Avatrombopag on the Treatment of Thrombocytopenia Induced by Chemotherapy of Malignant Tumors
Status:
Recruiting
Trial end date:
2021-08-31
Target enrollment:
Participant gender:
Summary
Tumor is one of the malignant diseases that people face. In 2015, the incidence of malignant
tumors was about 3.929 million, and the annual growth rate is about 3.9%. Chemotherapy is
currently the most commonly used treatment for patients with tumor, but chemotherapy also
brings many other problems, such as thrombocytopenia which can leads to increased medical
costs, chemotherapy cycles delayed, and chemotherapy doses reduced. Studies have found that
the reduction of the chemotherapy dose and the delay of the chemotherapy cycle will affect
the survival rate of patients. So it is an important to solve the problem of
chemotherapy-induced thrombocytopenia.
Currently, there are some methods to treat thrombocytopenia such as platelet transfusion,
rhTPO, rhIL-11 and other methods. However, these methods have some defects, platelets are at
risk of ineffective transfusion, rhTPO may produce neutralizing antibodies and rhIL-11 has
serious side effects. Therefore, there is an urgent need for safer and faster methods to
treat chemotherapy-induced thrombocytopenia. As a new generation of TPO receptor agonist,
avatrombopag has the advantages of being taken with food, no hepatotoxicity, good safety, and
rapidly increase platelet count. Therefore, avatrombopag has great research value in the
treatment of chemotherapy-induced thrombocytopenia.
Phase:
N/A
Details
Lead Sponsor:
Anhui Provincial Cancer Hospital
Collaborator:
Shanghai Fosun Pharmaceutical Development Co, Ltd.